Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Accumulated Expenses (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Accumulated Expenses data on record, last reported at $8.0 million in Q1 2025.

  • For Q1 2025, Accumulated Expenses rose 126.76% year-over-year to $8.0 million; the TTM value through Mar 2025 reached $8.0 million, up 126.76%, while the annual FY2024 figure was $7.2 million, 35.14% up from the prior year.
  • Accumulated Expenses reached $8.0 million in Q1 2025 per GLUE's latest filing, up from $7.2 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $8.0 million in Q1 2025 and bottomed at $3.2 million in Q1 2023.
  • Average Accumulated Expenses over 3 years is $5.5 million, with a median of $5.3 million recorded in 2023.
  • Peak YoY movement for Accumulated Expenses: increased 9.08% in 2024, then skyrocketed 126.76% in 2025.
  • A 3-year view of Accumulated Expenses shows it stood at $5.3 million in 2023, then skyrocketed by 35.14% to $7.2 million in 2024, then rose by 11.29% to $8.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $8.0 million in Q1 2025, $7.2 million in Q4 2024, and $6.7 million in Q3 2024.